Podcast 12 Jan 2024
Could natural killer cells transform Alzheimer’s treatment?
Join Dr. Paul Song, CEO of NKGen Biotech, in a podcast exploring the revolutionary use of NK cells for Alzheimer’s treatment.
Cell therapy
- Latest Posts
Best in Biotech 11 Jan 2024
Ten NK cell therapy companies to look out for this year
As biotechs raise funding to advance their NK cell therapy candidates in the clinic, here are ten companies in the space to watch out for.
Best in Biotech 19 Dec 2023
Nine biotech companies to watch in 2024
2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024.
Podcast 10 Nov 2023
How biotech can mend a broken heart
CellProthera has been working to do the impossible – mend broken hearts. The biotech company’s ProtheraCytes cell therapy regenerates damaged tissue following a heart attack, thus restoring cardiac function. In this podcast, we investigate regenerative therapy with CellProthera’s CEO, Matthieu de Kalbermatten. While regenerative cell therapy is dependent on the patient’s own cells, and reliant […]
Podcast 27 Oct 2023
Beyond Biotech podcast 69 – improving access to cell and gene therapy
This week, our guest on the podcast is Jason C. Foster, CEO of Ori Biotech. Ori is a London, U.K. and New Jersey, U.S. based manufacturing technology company pioneering flexible process discovery with translation and scalable commercialization of cell and gene therapies (CGT), increasing access to these innovative treatments. Ori has developed a proprietary, full […]
In Depth 4 Oct 2023
CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off?
Riding on the success of CAR-T cell therapy, a breakthrough in the treatment of blood cancers, CAR-NK therapies are an emerging field in therapeutic research that aim to boost an even stronger immune response against cancer. What is CAR-NK cell therapy? Natural killer (NK) cells, like T cells, are white blood cells that are a […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 27 Jul 2023
Cell and gene therapy manufacturing: trends, advancements and challenges
Cell and gene therapy manufacturing has been a pertinent topic for a while now, largely due to the fact it is such a complicated process, involving a number of moving parts and excessive costs. As such, figuring out how to make these types of therapies scalable, less time consuming and cost-effective is still an ongoing […]
Podcast 14 Jul 2023
Beyond Biotech podcast 54
1:24 Labiotech news3:45 TolerogenixX This week, we have a conversation with Matthias Schaier, CEO of TolerogenixX, about tackling rejection of organs following transplantation. TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant […]
News and Trends 11 Jul 2023
NK:IO awarded £1.6M grant to develop NK cell therapy
NK:IO, a U.K. company working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, has been awarded £1.6 million ($2.1 million) in grant funding from Innovate UK’s New Cancer Therapeutics program. The funding will support preclinical development, including development of a manufacturing process in collaboration […]
News and Trends 7 Jul 2023
TolerogenixX expands trial and closes €12M financing
TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression […]
News and Trends 6 Jul 2023
LIfT produces neutrophil-based cell therapy from iPSCs
LIfT BioSciences has announced successful proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). The proof-of-concept using iN-LIfT, the company’s second-generation platform, which is derived from iPSCs (a type of cell that has been reprogrammed so it is capable of becoming any type of cell) has shown that the alpha […]
News and Trends 27 Jun 2023
Astraveus exits stealth to advance cell and gene therapy platform
Astraveus SAS has emerged from stealth with the completion of an oversubscribed €16.5 million ($18.1 million) Series Seed financing. The company creates modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing. Astraveus has developed the Lakhesys platform, an end-to-end cell foundry that uses deep process optimization and single-use, microfluidic bioprocessors to deliver […]
ADVERTISEMENT
